LEFT-SIDED PORTAL HYPERTENSION SECONDARY TO LOCALLY ADVANCED PANCREATIC CANCER: CLINICAL CHARACTERISTICS, THERAPEUTIC APPROACH AND OUTCOME. MULTICENTRIC INTERNATIONAL REGISTER.
V 1.0. 29/Jan/2021
Left-sided portal hypertension (LSPH), also known as sinistral or segmental hypertension, is a localized form of portal hypertension (PH) that usually occurs as a result of splenic vein thrombosis (SVT) (1,2). It represents less than 5% of all cases of PH, distinguished from other forms by preserved liver function and patent extrahepatic portal vein (3).
Protocol_LSPH secondary to PC_Jan 2021 V1.0
VALL D’HEBRON UNIVERSITY HOSPITAL RESEARCH ETHICS COMMITTEE WITH MEDICINES AND RESEARCH PROJECT COMMISSION REPORT
Mrs. MIREIA NAVARRO SEBASTIÁN, Secretary of the Research Ethics Committee with Medicines of the Hospital Universitari Vall d’Hebron from Barcelona
CERTIFIES
The Hospital Universitari Vall d’Hebron Research Ethics Committee with Medicines, in which the research project commission is integrated, met in regular session No 481 last 26/03/2021 and evaluated the research project PR(AG)88/2021, entitled ” LEFT-SIDED PORTAL HYPERTENSION SECONDARY TO LOCALLY ADVANCED PANCREATIC CANCER: CLINICAL CHARACTERISTICS, THERAPEUTIC APPROACH AND OUTCOME. MULTICENTRIC INTERNATIONAL REGISTER” whose principal investigator Dr. Macarena Simon-Talero Horga, Internal Medicine-
Hepatology service of our center.
The result of the evaluation was as follows: Approved
PR(AG)88-2021 Dra. Macarena Simon-Talero_inglés